UBS Group started coverage on shares of First Tracks Biotherapeutics (NASDAQ:TRAX – Free Report) in a report released on Tuesday, MarketBeat Ratings reports. The firm issued a buy rating and a $45.00 price target on the stock.
First Tracks Biotherapeutics Stock Performance
NASDAQ TRAX opened at $17.00 on Tuesday. First Tracks Biotherapeutics has a 1 year low of $14.79 and a 1 year high of $26.80.
Recommended Stories
Receive News & Ratings for First Tracks Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Tracks Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
